Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
NAT2 encodes an enzyme that functions to both activate and deactivate arylamine and hydrazine drugs and carcinogens. Additionally we are shipping NAT2 Proteins (9) and NAT2 Kits (1) and many more products for this protein.
Showing 10 out of 63 products:
Human Polyclonal NAT2 Primary Antibody for WB - ABIN2781757
Ricco, Cau, Marchand, Marty, Rodde-Dunet, Fender, Allemand, Corsini: Stent-graft repair for thoracic aortic disease: results of an independent nationwide study in France from 1999 to 2001. in The Journal of thoracic and cardiovascular surgery 2006
Review/Meta-analysis: NAT2 (show SLC38A1 Antibodies) slow acetylation genotype is associated with an increased bladder cancer risk in Chinese individuals.
six selected NAT2 (show SLC38A1 Antibodies) exonic single nucleotide polymorphisms were genotyped in an independent case-control sample of a Northern Chinese Han population to verify the possible association between NAT2 (show SLC38A1 Antibodies) and schizophrenia. Three (rs1801280T/341C, rs1799930/G590A, and rs1208/A803G) of the six single nucleotide polymorphisms showed significant allele frequency differences between the case and the control groups.
Our findings suggested that NAT2 (show SLC38A1 Antibodies) gene polymorphism rs1799931 was associated with decreased risk of acute myeloid leukemia (show BCL11A Antibodies) and was likely to be a protective factor against acute myeloid leukemia (show BCL11A Antibodies) development.
Study reestablished the association between NAT2 (show SLC38A1 Antibodies) SA and isoniazid-induced liver injury in a Singaporean population and demonstrated its clinical validity in prediction of isoniazid-induced liver injury.
In non-syndromic cleft lip with or without cleft palate, we found a significant association between the EGF61 (rs4444903) and NSCL (show NHLH1 Antibodies)/P (P = .01) genes. Conversely, NAT2 (show SLC38A1 Antibodies) (rs1799929) was not significantly different between the cases and the control group
182 Hungarian bladder cancer cases and 78 cancer-free controls were investigated. It was not possible to establish a particular impact of NAT2 (show SLC38A1 Antibodies)*6A and *7B genotypes (15 cases, 8%, 5 controls, 7%). GSTT1 (show GSTT1 Antibodies) exerted no marked influence on bladder cancer (negative 21% cases vs. 22% controls). The portion of GSTM1 (show GSTM1 Antibodies) negative bladder cancer patients was increased (63% cases vs. 54% controls).
Various antitubercular isoniazid dosing regimens have been proposed for NAT2 (show SLC38A1 Antibodies)-specific immunocompetent and immune-deficient patient populations.
Data suggest that metabolism (and possibly pharmacokinetics) of hypnotic nitrazepam involves liver enzymes AOX1 (aldehyde oxidase 1 (show AOX1 Antibodies)), NAT2 (N-acetyltransferase 2), AADAC (arylacetamide deacetylase (show AADAC Antibodies)), and CYP3A4 (cytochrome P450 3A4 (show CYP3A4 Antibodies)).
The multicolor melting curve assay described in our study is very promising for the efficient determination of NAT2 (show SLC38A1 Antibodies) genotype, and can facilitate the personalized dosing of isoniazid
No significant differences in the acetylator NAT2 (show SLC38A1 Antibodies) haplotype and phenotype distributions were found between Native American populations practicing farming and/or herding and those practicing hunting and gathering.
Changes in transporter expression likely reflect different amino acid requirements during development. Findings include the differential expression of SNAT1 (show SLC38A1 Antibodies) in the inner and outer cells of the compacted morula and nuclear localisation of SNAT2 (show SLC38A2 Antibodies) in the trophectoderm and placental lineages.
This study illustrated that deficiency of NAT1/2 decreases isoniazid (INH) acetylation, but increases the interactions of INH with endobiotics in the liver.
Overexpression of X-box binding protein-1 (show XBP1 Antibodies) led to a marked increase in luciferase activity in P19 (show CDKN2D Antibodies) cells transfected with the Slc38a1 (show SLC38A1 Antibodies) reporter plasmid. These results suggest that theanine accelerates cellular proliferation and subsequent neuronal specification through a mechanism relevant to upregulation of Slc38a1 (show SLC38A1 Antibodies) gene in undifferentiated neural progenitor cells
We found that MeCP2 acts as a microglia-specific transcriptional repressor of
It was concluded that an acute colonic inflammation impairs the expression and function of NAT2 enzyme, thereby diminishing the capacity for 5-aminosalisylic acid metabolism by colonic mucosa.
GlnT (show SLC38A1 Antibodies) would promote both proliferation and neuronal differentiation through a mechanism relevant to the upregulation of particular proneural genes in undifferentiated P19 (show CDKN2D Antibodies) cells.
Inner hair cells express glutamine transporter SLC38A1 (show SLC38A1 Antibodies).
Hyperhomocysteinemia-induced decrease of peroxynitrite level is associated with an increase of hepatic Nat2 isoform activity with a reversal effect of wine polyphenol extract supplementation.
In this study, the in vivo endothelial membrane localization of the sodium-dependent glutamine (show GFPT1 Antibodies) transporters Snat3 (Slc38a3 (show SLC38A3 Antibodies)) and Snat1 (Slc38a1 (show SLC38A1 Antibodies)) was investigated in the mouse brain microvasculature.
Mouse NAT2 is likely to influence epigenetic gene control, particularly of its own locus, and this is consistent with recent evidence associating aberrant mouse Nat2/human NAT1 (show EIF4G2 Antibodies) gene expression with certain developmental malformations and cancers.
The study is the first to thoroughly characterize the properties of a polymorphic NAT isoenzyme in a non-human primate model.
This gene encodes an enzyme that functions to both activate and deactivate arylamine and hydrazine drugs and carcinogens. Polymorphisms in this gene are responsible for the N-acetylation polymorphism in which human populations segregate into rapid, intermediate, and slow acetylator phenotypes. Polymorphisms in this gene are also associated with higher incidences of cancer and drug toxicity. A second arylamine N-acetyltransferase gene (NAT1) is located near this gene (NAT2).
, N-Acetyltransferase-2 (arylamine N-acetyltransferase)
, N-acetyltransferase 2 (arylamine N-acetyltransferase)
, N-acetyltransferase type 2
, arylamide acetylase 2
, arylamine N-acetyltransferase 2
, N-acetyl transferase 2
, lambda R-1
, polymorphic arylamine N-acetyltransferase
, Arylamide acetylase 2
, NAT2 15
, Polymorphic arylamine N-acetyltransferase
, arylamine N-acetyltransferase-2
, N-system amino acid transporter 2
, amino acid transporter A1
, sodium-coupled neutral amino acid transporter 1
, system A amino acid transporter 1
, system N amino acid transporter 1